In the present study, we observed that the 2-year probabilities of relapse, NRM, LFS, and OS after allo-HSCT were 14.3%, 35.7%, 50.0%, and 50.0%, respectively, in AML patients with DEK-NUP214 transcripts. This evidence concerns the gene NUP214 and acute myeloid leukemia.